AWA
VVOS icon

Acorn Wealth Advisors’s Vivos Therapeutics VVOS Stock Holding History

Acorn Wealth Advisors’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.4K Hold
14,776
– – 0.01% 263
2025
Q4 		$30K Buy
+14,776
New +$36.6K 0.01% 266

Other funds holding VVOS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
IWM
IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return
CWM
Centurion Wealth Management Mclean, Virginia $418M AUM 23.14% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Acorn Wealth Advisors's VVOS Position: Q1 2026 in Review

Acorn Wealth Advisors held its Vivos Therapeutics (VVOS) position steady in Q1 2026 at 14,776 shares worth $17.4K. The position accounts for 0.01% of the portfolio, ranked #263.

Acorn Wealth Advisors first reported a position in VVOS in Q4 2025 and has held it in 2 quarters since. The position peaked at $30K in Q4 2025. 24 funds tracked by Wall St. Rank hold VVOS as of Q1 2026.

  • Acorn Wealth Advisors held 14,776 shares of Vivos Therapeutics worth $17.4K as of Q1 2026.
  • Acorn Wealth Advisors left its Vivos Therapeutics share count unchanged in Q1 2026.
  • Vivos Therapeutics made up 0.01% of Acorn Wealth Advisors's portfolio in Q1 2026, its #263 holding.
  • Acorn Wealth Advisors first reported a position in Vivos Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Acorn Wealth Advisors's Vivos Therapeutics position peaked at $30K in Q4 2025.
  • 24 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q1 2026.

Based on Acorn Wealth Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.